SCHEMBL503548

SCHEMBL503548

Cc1ccc2c(C[C@H](N)C(=O)O)c[nH]c2c1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 3/20 0.66
KDM4E B2RXH2 3/20 0.66
MAPT P10636 3/20 0.66
BLM P54132 3/20 0.66
LMNA P02545 2/20 0.66
TSHR P16473 2/20 0.66
PMP22 Q01453 2/20 0.66
MEN1 O00255 2/20 0.66
MPO P05164 1/20 0.66
HIF1A Q16665 1/20 0.66
PTPRA P18433 1/20 0.65
CYP2C19 P33261 1/20 0.62
HTR2A P28223 2/20 0.61
NPSR1 Q6W5P4 2/20 0.61
ALDH1A1 P00352 1/20 0.61
CYP3A4 P08684 1/20 0.61
HTR1A P08908 1/20 0.61
ADORA3 P0DMS8 1/20 0.61
ALOX15 P16050 1/20 0.61
NFKB1 P19838 1/20 0.61

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8769008 1.00 KMT2A (0.66) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL29809822 1.00 KMT2A (0.66) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL31036029 1.00 KMT2A (0.66) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL503549 1.00 KMT2A (0.66) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL24113516 0.89 SCN9A (0.59) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL41266 0.89 KMT2A (0.73) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL30310502 0.89 SCN9A (0.59) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL16975865 0.89 HTR2A (0.55) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL41267 0.89 KMT2A (0.73) KMT2AKDM4EMAPTBLMLMNA
SCHEMBL29527694 0.89 KMT2A (0.73) KMT2AKDM4EMAPTBLMLMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 965 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260144842-A1 PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS TEMPLE OTORONGO LLC (US) 2026-05-28 US claimed
US-12600699-B2 Thiosemicarbazates and uses thereof THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2026-04-14 US claimed
US-12351573-B2 Compounds for use in synthesis of peptidomimetics THE FEINSTEIN INSTITUTES FOR MEDICAL RESEARCH (US) 2025-07-08 US claimed
WO-2025109003-A1 P-CADHERIN LIGANDS 3B PHARMACEUTICALS GMBH (DE) 2025-05-30 WO claimed
CN-118406439-B Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing 万华化学集团电子材料有限公司 2024-10-18 CN claimed
EP-4274838-B1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LTD (GB) 2024-09-25 EP claimed
CN-118406439-A Chemical mechanical polishing composition and application thereof in tungsten chemical mechanical polishing 万华化学集团电子材料有限公司 2024-07-30 CN claimed
CN-118184756-A Engineered Leptospira perfoliatum lectin mutant and application thereof 浙江大学医学院附属第一医院(浙江省第一医院) 2024-06-14 CN claimed
US-20240108738-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS BICYCLETX LIMITED (GB) 2024-04-04 US claimed
US-11904020-B2 Bicyclic peptide ligands specific for TREM2 BICYCLETX LIMITED (GB) 2024-02-20 US claimed
EP-1372571-A4 METHOD AND COMPOSITIONS FOR OPTIMIZING BLOOD AND TISSUE STABILITY OF CAMPTOTHECIN AND OTHER ALBUMIN-BINDING THERAPEUTIC COMPOUNDS NEW CENTURY PHARMACEUTICALS (US) 2006-06-07 EP claimed
WO-2005097820-A1 PEPTIDES FOR INHIBITING MDM2 FUNCTION KOREA RESEARCH INSTITUTE OF BIOSCIENCE AND BIOTECHNOLOGY (KR) 2005-10-20 WO claimed
EP-1372571-A2 METHOD AND COMPOSITIONS FOR OPTIMIZING BLOOD AND TISSUE STABILITY OF CAMPTOTHECIN AND OTHER ALBUMIN-BINDING THERAPEUTIC COMPOUNDS New Century Pharmaceuticals, Inc. (US) 2004-01-02 EP claimed
US-20020193318-A1 Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds NEW CENTURY PHARMACEUTICALS, INC. 2002-12-19 US claimed
WO-2002074246-A2 METHOD AND COMPOSITIONS FOR OPTIMIZING BLOOD AND TISSUE STABILITY OF CAMPTOTHECIN AND OTHER ALBUMIN-BINDING THERAPEUTIC COMPOUNDS NEW CENTURY PHARMACEUTICALS, INC. (US) 2002-09-26 WO claimed
EP-1101823-A2 Process for the preparation of indigo derivatives and dyes for ceratinous fibers containing the same Wella Aktiengesellschaft (DE) 2001-05-23 EP claimed
US-5034318-A Culturing Coryneform glutamic acid producing bacteria with plasmids AJINOMOTO CO., INC. (JP) 1991-07-23 US claimed
EP-0136359-A1 PROCESS FOR PREPARING L-HISTIDINE KYOWA HAKKO KOGYO KABUSHIKI KAISHA (JP) 1985-04-10 EP claimed
US-4371614-A E.Coli bacteria carrying recombinant plasmids and their use in the fermentative production of L-tryptophan AJINOMOTO CO., INC. (JP) 1983-02-01 US claimed
US-3930948-A ENZYMATIC METHOD FOR PRODUCING AROMATIC ETHYLAMINES AJINOMOTO CO., INC. (JA) 1976-01-06 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12351573-B2 Compounds for use in synthesis of peptidomimetics DNPEP, NPEPPS, PAM KMT2A 1848/4885KDM4E 3819/4885MAPT 1350/4885
US-11904020-B2 Bicyclic peptide ligands specific for TREM2 APP, TIMCC, ADM2 KMT2A 3481/4885KDM4E 4811/4885MAPT 308/4885
US-20260144842-A1 PHARMACEUTICAL COMPOSITION COMPRISING TRYPTOPHAN AND PHYLLOKININ DERIVATIVE FOR USE IN TREATING PSYCHIATRIC AND PSYCHOLOGICAL CONDITIONS OPRK1, TPH1, HTR3C KMT2A 4104/4885KDM4E 4515/4885MAPT 1093/4885
US-20240108738-A1 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR NK CELLS PBK, KLRK1, MICA KMT2A 1977/4885KDM4E 1930/4885MAPT 4099/4885
US-12600699-B2 Thiosemicarbazates and uses thereof MET, THRB, ABAT KMT2A 2188/4885KDM4E 2649/4885MAPT 1679/4885
US-20020193318-A1 Methods and compositions for optimizing blood and tissue stability of camptothecin and other albumin-binding therapeutic compounds ALB, TYMP, SHBG KMT2A 3823/4885KDM4E 3521/4885MAPT 670/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.